Barinthus Biotherapeutics Plc logo

Barinthus Biotherapeutics Plc Share Price Today

(NASDAQ: BRNS)

Barinthus Biotherapeutics Plc share price is $1.03 & ₹90.05 as on 8 Feb 2025, 2.30 'hrs' IST

$1.03

0.03

(3%)

Market is closed - opens 8 PM, 10 Feb 2025

View live Barinthus Biotherapeutics Plc share price in Dollar and Rupees. Guide to invest in Barinthus Biotherapeutics Plc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Barinthus Biotherapeutics Plc, along with analyst recommendations, forecasts, and comprehensive financials.

Barinthus Biotherapeutics Plc share price movements

  • Today's Low: $1.01
    Today's High: $1.10

    Day's Volatility :8.64%

  • 52 Weeks Low: $0.80
    52 Weeks High: $4.16

    52 Weeks Volatility :80.75%

Barinthus Biotherapeutics Plc (BRNS) Returns

PeriodBarinthus Biotherapeutics PlcIndex (Russel 2000)
3 Months
-25.0%
0.0%
6 Months
-23.13%
0.0%
1 Year
-59.49%
0.0%
3 Years
-88.96%
-13.8%

Barinthus Biotherapeutics Plc (BRNS) Key Statistics

in dollars & INR

Previous Close
$1.0
Open
$1.01
Today's High
$1.1
Today's Low
$1.005
Market Capitalization
$40.2M
Today's Volume
$62.1K
52 Week High
$4.1591
52 Week Low
$0.8008
Revenue TTM
$15.0M
EBITDA
$-59.8M
Earnings Per Share (EPS)
$-1.49
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-32.6%

How to invest in Barinthus Biotherapeutics Plc Stock (BRNS) from India?

It is very easy for Indian residents to invest directly in Barinthus Biotherapeutics Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Barinthus Biotherapeutics Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Barinthus Biotherapeutics Plc or BRNS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Barinthus Biotherapeutics Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Barinthus Biotherapeutics Plc shares which would translate to 0.849 fractional shares of Barinthus Biotherapeutics Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Barinthus Biotherapeutics Plc, in just a few clicks!

Returns in Barinthus Biotherapeutics Plc (BRNS) for Indian investors in Rupees

The Barinthus Biotherapeutics Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Barinthus Biotherapeutics Plc investment value today

Current value as on today

₹45,887

Returns

₹54,113

(-54.11%)

Returns from Barinthus Biotherapeutics Plc Stock

₹59,449 (-59.45%)

Dollar Returns

₹5,336 (+5.34%)

Indian investors sentiment towards Barinthus Biotherapeutics Plc (BRNS)

-87%

Period: Jan 10, 2025 to Feb 9, 2025. Change in 30 Days versus previous period

Search interest for Barinthus Biotherapeutics Plc Stock from India on INDmoney has decreased by -87% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Barinthus Biotherapeutics Plc

    Analyst Recommendation on Barinthus Biotherapeutics Plc

    Buy

      83%Buy

      16%Hold

      0%Sell

    Based on 12 Wall street analysts offering stock ratings for Barinthus Biotherapeutics Plc(by analysts ranked 0 to 5 stars)

    Based on 12 analyst
    • Current
    • 1M Ago
    • 3M Ago
    Buy
    10
    10
    10
    Hold
    2
    2
    2
    Sell
    0
    0
    0

    Analyst Forecast on Barinthus Biotherapeutics Plc Stock (BRNS)

    What analysts predicted

    Upside of 506.8%

    Target:

    $6.25

    Current:

    $1.03

    Insights on Barinthus Biotherapeutics Plc Stock (Ticker Symbol: BRNS)

    • Price Movement

      In the last 3 years, BRNS stock has moved down by -89.2%
    • Increasing Revenue

      Revenue is up for the last 3 quarters, 334.0K → 14.96M (in $), with an average increase of 79.0% per quarter
    • Increasing Net Profit

      Netprofit is up for the last 2 quarters, -16.94M → -8.11M (in $), with an average increase of 108.9% per quarter
    • BRNS vs ALNY (1 yr)

      In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.4% return, outperforming this stock by 122.2%
    • BRNS vs VRTX (3 yr)

      In the last 3 years, Vertex Pharmaceuticals Incorporated has given 83.1% return, outperforming this stock by 172.3%
    • Price to Sales

      ForBRNS every $1 of sales, investors are willing to pay $2.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.7 for every $1 of sales.

    Barinthus Biotherapeutics Plc Technicals Summary

    Sell

    Neutral

    Buy

    Barinthus Biotherapeutics Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

    Barinthus Biotherapeutics Plc (BRNS) Vs Peers

    Company Name1 Month6 Month1 Year3 Years5 Years
    Barinthus Biotherapeutics Plc logo
    9.57%
    -23.13%
    -59.49%
    -88.96%
    -93.06%
    Biontech Se logo
    3.4%
    45.88%
    25.3%
    -31.2%
    297.87%
    Regeneron Pharmaceuticals, Inc. logo
    -0.96%
    -36.67%
    -25.03%
    11.21%
    74.75%
    Vertex Pharmaceuticals Incorporated logo
    13.54%
    1.04%
    12.14%
    100.66%
    93.77%
    Alnylam Pharmaceuticals, Inc. logo
    6.94%
    2.22%
    63.1%
    83.2%
    106.13%
    Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
    Barinthus Biotherapeutics Plc logo
    NA
    NA
    NA
    -1.48
    -0.33
    -0.19
    NA
    4.03
    Biontech Se logo
    160.8
    NA
    0.04
    -3.29
    -0.02
    -0.01
    NA
    79.73
    Regeneron Pharmaceuticals, Inc. logo
    18.83
    18.83
    1.15
    43.84
    0.17
    0.07
    NA
    272.04
    Vertex Pharmaceuticals Incorporated logo
    32.84
    NA
    1.28
    0.48
    -0.03
    0.12
    NA
    60.65
    Alnylam Pharmaceuticals, Inc. logo
    NA
    NA
    -0.49
    -0.18
    -15.01
    -0.03
    NA
    0.25
    Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
    Barinthus Biotherapeutics Plc logo
    Buy
    $40.2M
    -93.06%
    NA
    0.0%
    Biontech Se logo
    Buy
    $28.8B
    297.87%
    160.8
    -15.36%
    Regeneron Pharmaceuticals, Inc. logo
    Buy
    $78.9B
    74.75%
    18.83
    33.61%
    Vertex Pharmaceuticals Incorporated logo
    Buy
    $123.9B
    93.77%
    32.84
    -4.51%
    Alnylam Pharmaceuticals, Inc. logo
    Buy
    $35.9B
    106.13%
    NA
    -15.86%

    About Barinthus Biotherapeutics Plc

    Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
    Organization
    Barinthus Biotherapeutics Plc
    Employees
    130
    CEO
    Mr. William J. Enright MBA
    Industry
    Miscellaneous

    Management People of Barinthus Biotherapeutics Plc

    NameTitle
    Mr. William J. Enright MBA
    CEO & Director
    Mr. Graham Griffiths
    Chief Operating Officer
    Ms. Sarah Gilbert
    Co-Founder
    Mr. Adrian Hill Ph.D.
    Co-Founder & Scientific Advisor
    Ms. Gemma Brown
    CFO & Company Secretary
    Dr. Geoffrey Lynn M.D., Ph.D.
    Chief Scientific Officer
    Ms. Elizabeth Eagling-Vose M.B.A.
    Head of Clinical Operations
    Bernie McDonald
    Head of IP
    Dr. Leon Hooftman M.D.
    Chief Medical Officer

    Important FAQs about investing in BRNS Stock from India :

    What is Barinthus Biotherapeutics Plc share price today?

    Barinthus Biotherapeutics Plc share price today stands at $1.03, Open: $1.01 ; Previous Close: $1.00 ; High: $1.10 ; Low: $1.01 ; 52 Week High: $4.16 ; 52 Week Low: $0.80.

    The stock opens at $1.01, after a previous close of $1.00. The stock reached a daily high of $1.10 and a low of $1.01, with a 52-week high of $4.16 and a 52-week low of $0.80.

    Can Indians buy Barinthus Biotherapeutics Plc shares?

    Yes, Indians can invest in the Barinthus Biotherapeutics Plc (BRNS) from India.

    With INDmoney, you can buy Barinthus Biotherapeutics Plc at 0 brokerage. The step-by-step process is as follows:

    • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
    • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
    • Once funds are transferred successfully, you can buy Barinthus Biotherapeutics Plc at zero transaction cost.

    How can I buy Barinthus Biotherapeutics Plc shares from India?

    It is very easy to buy Barinthus Biotherapeutics Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

    Can Fractional shares of Barinthus Biotherapeutics Plc (BRNS) be purchased?

    Yes, you can buy fractional shares of Barinthus Biotherapeutics Plc with INDmoney app.

    What are the documents required to start investing in Barinthus Biotherapeutics Plc stocks?

    To start investing in Barinthus Biotherapeutics Plc, You will need the following documents:

    • Proof of Identification (PAN, Aadhaar etc)
    • Proof of address (Aadhaar, Voter ID etc)

    These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

    What are today’s High and Low prices of Barinthus Biotherapeutics Plc Stock (BRNS)?

    Today’s highest price of Barinthus Biotherapeutics Plc (BRNS) is $1.10.

    Today’s lowest price of Barinthus Biotherapeutics Plc (BRNS) is $1.01.

    What is today's market capitalisation of Barinthus Biotherapeutics Plc?

    Today's market capitalisation of Barinthus Biotherapeutics Plc BRNS is 40.2M

    What is the 52 Week High and Low Range of Barinthus Biotherapeutics Plc Stock (BRNS)?

    • 52 Week High

      $4.16

    • 52 Week Low

      $0.80

    What are the historical returns of Barinthus Biotherapeutics Plc (BRNS)?

    • 1 Month Returns

      9.57%

    • 3 Months Returns

      -23.13%

    • 1 Year Returns

      -59.49%

    • 5 Years Returns

      -93.06%

    Who is the Chief Executive Officer (CEO) of Barinthus Biotherapeutics Plc ?

    Mr. William J. Enright MBA is the current Chief Executive Officer (CEO) of Barinthus Biotherapeutics Plc.